NCT01514851 is a Phase 3 clinical trial of Lanthanum carbonate (BAY77-1931) in Hyperphosphatemia, sponsored by Bayer.

Who is sponsoring NCT01514851?

NCT01514851 is sponsored by Bayer.

What drugs are being tested in NCT01514851?

Interventions in NCT01514851: Lanthanum carbonate (BAY77-1931), Calcium carbonate.

What condition does NCT01514851 study?

NCT01514851 studies Hyperphosphatemia.

Is NCT01514851 still recruiting?

NCT01514851 is currently completed. Last updated 7 June 2012.

Last reviewed 2012-06-07 · How we verify

NCT01514851

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase III Double-blind Comparative Study of BAY 77 1931 (Lanthanum Carbonate) With a Calcium Carbonate in Patients With Hyperphosphatemia Undergoing Hemodialysis

Completed Phase 3 Last updated 7 June 2012

What this trial tests

Phase 3 trial testing Lanthanum carbonate (BAY77-1931) in Hyperphosphatemia in 259 participants. Completed in 1 May 2006.

Timeline

1 January 2006

Primary endpoint
1 May 2006

1 May 2006

Quick facts

Lead sponsor	Bayer
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	259
Start date	1 January 2006
Primary completion	1 May 2006
Estimated completion	1 May 2006
Sites	31 locations across Japan

Drugs / interventions tested

Lanthanum carbonate (BAY77-1931) — full drug profile →
Calcium carbonate (calcium carbonate) — full drug profile →

Conditions studied

Hyperphosphatemia — all drugs for Hyperphosphatemia →

Sponsor

Bayer — full company profile →

Who can join

20 and older, any sex, with Hyperphosphatemia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change from baseline in pre-dialysis serum phosphate levels (PSPL) at the end of the double-blind period
Time frame: baseline to week 8
Presence/absence of incidence of hypercalcemia up to 8 weeks
Time frame: up to 8 weeks

Sponsor's own description

To assess the effect on reduction of serum phosphate and the safety of BAY77-1931 (Lanthanum Carbonate) in patients with hyperphosphatemia undergoing hemodialysis in a randomized, double-blind, parallel group study in comparison with Calcium carbonate.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hyperphosphatemia

Currently open trials in the same condition.

NCT06933472 — A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China · Phase 3 · recruiting
NCT06664125 — Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemi · Phase 2 · recruiting
NCT06206135 — Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Capsule · recruiting
NCT06186934 — Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea Patients · recruiting
NCT03573089 — Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE) · NA · recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01514851 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 7 June 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01514851.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing